OTUD3 — OTU Deubiquitinase 3
<table class="infobox infobox-gene">
<tr>
<th class="infobox-header" colspan="2">OTUD3 — OTU Deubiquitinase 3</th>
</tr>
<tr>
<td class="label">Symbol</td>
<td><strong>OTUD3</strong></td>
</tr>
<tr>
<td class="label">Full Name</td>
<td>OTU Deubiquitinase 3</td>
</tr>
<tr>
<td class="label">Chromosome</td>
<td>17p13.1</td>
</tr>
<tr>
<td class="label">NCBI Gene</td>
<td><a href="https://www.ncbi.nlm.nih.gov/gene/57567" target="_blank">57567</a></td>
</tr>
<tr>
<td class="label">Ensembl</td>
<td><a href="https://ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000167695" target="_blank">ENSG00000167695</a></td>
</tr>
<tr>
<td class="label">OMIM</td>
<td><a href="https://omim.org/entry/607375" target="_blank">607375</a></td>
</tr>
<tr>
<td class="label">UniProt</td>
<td><a href="https://www.uniprot.org/uniprot/Q5T7Q2" target="_blank">Q5T7Q2</a></td>
</tr>
<tr>
<td class="label">PARK Locus</td>
<td>PARK11</td>
</tr>
<tr>
<td class="label">Diseases</td>
<td><a href="/diseases/parkinsons-disease">Parkinson's Disease</a></td>
</tr>
<tr>
<td class="label">Expression</td>
<td>Brain, Heart, Kidney, Liver</td>
</tr>
<tr>
<td class="label">Associated Diseases</td>
<td><a href="/wiki/als" style="color:#ef9a9a">Als</a>, <a href="/wiki/cancer" style="color:#ef9a9a">Cancer</a>, <a href="/wiki/tumor" style="color:#ef9a9a">Tumor</a></td>
</tr>
<tr>
<td class="label">KG Connections</td>
<td><a href="/atlas" style="color
...
OTUD3 — OTU Deubiquitinase 3
<table class="infobox infobox-gene">
<tr>
<th class="infobox-header" colspan="2">OTUD3 — OTU Deubiquitinase 3</th>
</tr>
<tr>
<td class="label">Symbol</td>
<td><strong>OTUD3</strong></td>
</tr>
<tr>
<td class="label">Full Name</td>
<td>OTU Deubiquitinase 3</td>
</tr>
<tr>
<td class="label">Chromosome</td>
<td>17p13.1</td>
</tr>
<tr>
<td class="label">NCBI Gene</td>
<td><a href="https://www.ncbi.nlm.nih.gov/gene/57567" target="_blank">57567</a></td>
</tr>
<tr>
<td class="label">Ensembl</td>
<td><a href="https://ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000167695" target="_blank">ENSG00000167695</a></td>
</tr>
<tr>
<td class="label">OMIM</td>
<td><a href="https://omim.org/entry/607375" target="_blank">607375</a></td>
</tr>
<tr>
<td class="label">UniProt</td>
<td><a href="https://www.uniprot.org/uniprot/Q5T7Q2" target="_blank">Q5T7Q2</a></td>
</tr>
<tr>
<td class="label">PARK Locus</td>
<td>PARK11</td>
</tr>
<tr>
<td class="label">Diseases</td>
<td><a href="/diseases/parkinsons-disease">Parkinson's Disease</a></td>
</tr>
<tr>
<td class="label">Expression</td>
<td>Brain, Heart, Kidney, Liver</td>
</tr>
<tr>
<td class="label">Associated Diseases</td>
<td><a href="/wiki/als" style="color:#ef9a9a">Als</a>, <a href="/wiki/cancer" style="color:#ef9a9a">Cancer</a>, <a href="/wiki/tumor" style="color:#ef9a9a">Tumor</a></td>
</tr>
<tr>
<td class="label">KG Connections</td>
<td><a href="/atlas" style="color:#4fc3f7">13 edges</a></td>
</tr>
</table>
OTUD3 — OTU Deubiquitinase 3
Overview
Mermaid diagram (expand to render)
OTUD3 (OTU Deubiquitinase 3), encoded by the OTUD3 gene on chromosome 17p13.1, is a member of the ovarian tumor (OTU) family of deubiquitinating enzymes. The gene has been implicated in Parkinson's disease (PD) as a potential causative gene for PARK11, though the pathogenicity of OTUD3 variants remains controversial and uncertain.
Introduction
OTUD3 was first linked to Parkinson's disease in 2014 when whole-exome sequencing studies identified rare variants in patients with familial PD[@yang2014][@shi2014]. However, subsequent studies have yielded conflicting results regarding the pathogenic nature of OTUD3 variants, and its role in PD pathogenesis remains uncertain compared to established PD genes like [LRRK2](/genes/lrrk2) or [SNCA](/genes/snca).
The OTUD3 protein functions as a deubiquitinase (DUB), an enzyme that removes ubiquitin chains from target proteins, thereby regulating protein stability, signaling pathways, and cellular homeostasis.
Structure
OTUD3 is a 524-amino acid protein with the following domain architecture:
OTU Domain (Residues 85-270)
The core catalytic domain shares homology with other OTU family deubiquitinases:
- Catalytic triad: Cys-His-Asp residues required for protease activity
- Ubiquitin-binding surface: Interacts with ubiquitin substrates
- zinc-finger motif: Stabilizes the domain structure
N-Terminal Region (Residues 1-84)
- Contains low-complexity sequences
- May mediate protein-protein interactions
C-Terminal Region (Residues 271-524)
- Regulatory functions
- Potential interaction motifs
Normal Function
Under physiological conditions, OTUD3 participates in several cellular processes:
Deubiquitination Activity
OTUD3 removes ubiquitin chains from target proteins:
- K48-linked chains: Typically target proteins for proteasomal degradation
- K63-linked chains: Regulate signaling complexes and endocytosis
- Linear chains: Regulate NF-κB signaling pathways
Cellular Pathways
- p53 pathway: OTUD3 can stabilize p53 by removing ubiquitination
- AKT signaling: Regulates AKT protein stability and signaling
- Cellular stress response: Involved in DNA damage repair
- Protein quality control: Maintains cellular proteostasis
Tissue Distribution
OTUD3 is expressed in multiple tissues:
- Brain: Neurons and glial cells
- Heart: Cardiac myocytes
- Kidney: Renal tubular cells
- Liver: Hepatocytes
Parkinson's Disease Association
Evidence for Pathogenic Role
The initial studies linking OTUD3 to PD reported:
Rare missense variants in familial PD patients
Loss-of-function variants that reduce deubiquitinase activity
Functional studies showing impaired mitophagy regulationControversy and Uncertainties
Subsequent investigations have raised questions about OTUD3's pathogenicity:
Limited segregation in affected families
Variable frequency in different populations
Lack of definitive functional validation in animal models
No robust replication in large cohort studiesCompared to established PD genes such as [LRRK2](/genes/lrrk2), [GBA](/genes/gba), or [SNCA](/genes/snca), OTUD3 remains a gene of uncertain significance in PD genetics.
Current Classification
- PARK11 status: Considered uncertain/controversial
- ACMG classification: Variants typically classified as variants of uncertain significance (VUS)
- Clinical utility: Not currently used for clinical testing
Therapeutic Implications
Given the uncertain pathogenicity of OTUD3 variants, therapeutic targeting remains speculative:
Potential Therapeutic Approaches
Deubiquitinase modulation: If OTUD3 loss-of-function contributes to PD, activating compounds could be beneficial
Protein stabilization: Enhancing OTUD3 expression or activity
下游 pathways: Targeting downstream effectors of OTUD3 deubiquitinase activityResearch Directions
- Better understanding of OTUD3 substrate specificity
- Development of cellular and animal models
- Correlation with clinical phenotypes
OTUD3 interacts with several PD-relevant pathways:
- [LRRK2](/genes/lrrk2): Both implicated in PD, though LRRK2 has stronger evidence
- [GBA](/genes/gba): Established PD gene involved in autophagy
- [SNCA](/genes/snca): Alpha-synuclein aggregation pathway
- [Ubiquitin-Proteasome System](/mechanisms/ubiquitin-proteasome-system): Core pathway for protein clearance
- [Mitophagy](/mechanisms/mitophagy-pathway): Mitochondrial quality control
References
[Sharif et al., OTUD3 deubiquitinase activity (2023)](https://doi.org/10.1016/j.jbc.2023.104928)
[Yang et al., OTUD3 suppresses Parkinson's disease pathogenesis (2014)](https://doi.org/10.1038/nn.3638)
[Shi et al., OTUD3 variants in patients with Parkinson's disease (2014)](https://doi.org/10.1001/jamaneurol.2014.1065)
[Miron et al., Structural basis for OTUD proteins (2018)](https://doi.org/10.1038/s41467-018-04150-7)